These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35346102)

  • 1. Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer.
    Amitani M; Oba T; Kiyosawa N; Morikawa H; Chino T; Soma A; Shimizu T; Ohno K; Ono M; Ito T; Kanai T; Maeno K; Ito KI
    BMC Cancer; 2022 Mar; 22(1):327. PubMed ID: 35346102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy.
    Kamitani N; Migita K; Matsumoto S; Wakatsuki K; Kunishige T; Nakade H; Miyao S; Sho M
    Surg Today; 2019 Dec; 49(12):1022-1028. PubMed ID: 31309328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
    Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
    BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy-induced decrease of prognostic nutrition index predicts poor prognosis in patients with breast cancer.
    Oba T; Maeno K; Takekoshi D; Ono M; Ito T; Kanai T; Ito KI
    BMC Cancer; 2020 Feb; 20(1):160. PubMed ID: 32106833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Impact of the Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy on Older Patients with Esophageal Cancer.
    Harada T; Tsuji T; Ueno J; Koishihara Y; Konishi N; Hijikata N; Ishikawa A; Kotani D; Kojima T; Fujiwara H; Fujita T
    Ann Surg Oncol; 2022 Dec; 29(13):8131-8139. PubMed ID: 35978207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in skeletal muscle index and its prognostic significance in patients who underwent successful conversion therapy for initially unresectable colorectal cancer: observational study.
    Nozawa H; Emoto S; Murono K; Shuno Y; Kawai K; Sasaki K; Sonoda H; Ishii H; Iida Y; Yokoyama Y; Anzai H; Ishihara S
    Therap Adv Gastroenterol; 2020; 13():1756284820971197. PubMed ID: 33240393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
    Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effect of enteral nutrition support during neoadjuvant chemotherapy on the preservation of skeletal muscle mass in patients with esophageal cancer.
    Kita R; Miyata H; Sugimura K; Tanaka K; Makino T; Yamashita K; Yamasaki M; Motoori M; Shiraishi O; Kimura Y; Yasuda T; Yano M; Doki Y
    Clin Nutr; 2021 Jun; 40(6):4380-4385. PubMed ID: 33526287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Skeletal Muscle Loss and Visceral Obesity Measured Using Serial CT on the Prognosis of Operable Breast Cancers in Asian Patients.
    Kwon MR; Ko ES; Park MS; Jeong WK; Hwang NY; Kim JH; Lee JE; Kim SW; Yu JH; Han BK; Ko EY; Choi JS; Park KW
    Korean J Radiol; 2022 Feb; 23(2):159-171. PubMed ID: 35029082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of the skeletal muscle index and systemic inflammatory index in patients with lymph node-positive breast cancer after radical mastectomy.
    Tang R; Deng JP; Zhang L; Zhang WW; Sun JY; Chi F; Zhang J; Wu SG; He ZY
    BMC Cancer; 2022 Mar; 22(1):234. PubMed ID: 35241010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bidirectional association between perioperative skeletal muscle and subcutaneous fat in colorectal cancer patients and their prognostic significance.
    Yan G; Liu L; Liu M; Jiang X; Chen P; Li M; Ma Q; Li Y; Duan S; You R; Huang Y; Li Z; You D
    Front Nutr; 2024; 11():1381995. PubMed ID: 39360277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of skeletal muscle wasting during neoadjuvant chemotherapy on postoperative anastomotic leakage in patients with esophageal cancer.
    Fujihata S; Ogawa R; Nakaya S; Hayakawa S; Okubo T; Sagawa H; Tanaka T; Takahashi H; Matsuo Y; Takiguchi S
    Esophagus; 2021 Apr; 18(2):258-266. PubMed ID: 32889673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer.
    Huang CY; Yang YC; Chen TC; Chen JR; Chen YJ; Wu MH; Jan YT; Chang CL; Lee J
    J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):534-546. PubMed ID: 31999069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative prognostic impact of sarcopenia before and after neoadjuvant chemotherapy for pancreatic cancer.
    Shimura M; Mizuma M; Motoi F; Kusaka A; Aoki S; Iseki M; Inoue K; Douchi D; Nakayama S; Miura T; Ishida M; Ohtsuka H; Nakagawa K; Morikawa T; Kamei T; Unno M
    Pancreatology; 2023 Jan; 23(1):65-72. PubMed ID: 36473785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body composition parameters predict pathological response and outcomes in locally advanced gastric cancer after neoadjuvant treatment: A multicenter, international study.
    Lin JX; Tang YH; Zhou WX; Desiderio J; Parisi A; Xie JW; Wang JB; Cianchi F; Antonuzzo L; Borghi F; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Staderini F; Marano A; Peluso C; Li P; Zheng CH; Ma YB; Huang CM
    Clin Nutr; 2021 Aug; 40(8):4980-4987. PubMed ID: 34364237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Skeletal Muscle Mass before Salvage-Line Chemotherapy Is a Poor Prognostic Factor in Patients with Refractory Metastatic Colorectal Cancer.
    Miyamoto Y; Hiyoshi Y; Akiyama T; Kiyozumi Y; Eto K; Yohei N; Iwagami S; Baba Y; Yoshida N; Baba H
    Digestion; 2019; 99(1):79-85. PubMed ID: 30554226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer.
    Park SE; Choi JH; Park JY; Kim BJ; Kim JG; Kim JW; Park JM; Chi KC; Hwang IG
    Sci Rep; 2020 Oct; 10(1):17683. PubMed ID: 33077864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy.
    Regnier P; DE Luca V; Brunelle S; Sfumato P; Walz J; Rybikowski S; Maubon T; Branger N; Fakhfakh S; Durand M; Gravis G; Pignot G
    Minerva Urol Nephrol; 2021 Apr; 73(2):215-224. PubMed ID: 32083413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does neoadjuvant chemotherapy regimen affect sarcopenia status in patients with breast cancer?
    Jang MK; Park S; Park C; Doorenbos AZ; Go J; Kim S
    Breast; 2022 Dec; 66():1-7. PubMed ID: 36063619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal Muscle Loss During Neoadjuvant Chemotherapy Predicts the Incidence of Postoperative Infectious Complications in Esophageal Cancer Patients Undergoing Esophagectomy.
    Higashizono K; Sato S; Nakatani E; Hawke P; Nagai E; Taki Y; Nishida M; Watanabe M; Oba N
    Cancer Diagn Progn; 2023; 3(1):67-74. PubMed ID: 36632592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.